|View printer-friendly version|
Array BioPharma Appoints Drs. S. Gail Eckhardt And Randall K. Johnson to Its Scientific Advisory Board
- New Members Bring Strong Oncology Expertise -
BOULDER, Colo., Feb. 19 /PRNewswire-FirstCall/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced the appointments of S. Gail Eckhardt, M.D. and Randall K. Johnson, Ph.D., to its Scientific Advisory Board.
"Drs. Eckhardt's and Johnson's extensive experience and outstanding reputation in anticancer drug development are a valuable asset for Array," said Kevin Koch, Ph.D., President and Chief Scientific Officer, Array BioPharma. "As cancer experts, both will contribute valuable knowledge and expertise as we move our oncology programs forward into clinical development."
"It is a great opportunity to participate in developing Array's promising drug pipeline," said Dr. Eckhardt. "I look forward to helping to guide the development of Array's breakthrough treatments for cancer as a member of the Scientific Advisory Board."
"I am delighted to be working with and advising Array BioPharma in drug development," said Dr. Johnson. "Array has world-class skills in medicinal chemistry and structural biology with rapidly expanding capabilities in pharmacology. I look forward to interacting with them as they build an innovative and successful pipeline in oncology."
Background - S. Gail Eckhardt, M.D.
Dr. Eckhardt, with over 14 years of oncology experience, is Professor of Medicine at the University of Colorado Health Sciences Center in Denver, Colorado, where she also serves as Director of the Developmental Therapeutics and GI Malignancies Programs. Prior to joining the University of Colorado, Dr. Eckhardt served as Associate Director of Clinical Research, and as Director of the Drug Development Fellowship Training Program at the Institute for Drug Development, Cancer Therapy and Research Center, in San Antonio, Texas.
Dr. Eckhardt is the Principal Investigator on two NIH grants involving early clinical trials research and has conducted numerous phase I and II clinical trials. She has published over 50 manuscripts and serves on numerous advisory boards. Dr. Eckhardt also serves on Board of Directors for the American Society of Clinical Oncology (ASCO) as well as committees and study sections, including the GI Steering Committee of the Southwest Oncology Group, the ASCO Molecular Oncology Task Force and the EORTC Early Clinical Trials Review Panel. She was also Chair of the ASCO Program Committee in 2003 and serves as an external reviewer for the Drug Development Group, National Cancer Institute. In addition, Dr. Eckhardt is an Associate Editor of the Journal of Clinical Oncology, Clinical Cancer Research, and Investigational New Drugs, and was recently named to the scientific advisory board of 5AM Ventures.
Dr. Eckhardt received her medical degree from the University of Texas Medical Branch in Galveston, Texas. She completed her internship and residency in internal medicine at the University of Virginia Medical Center in Charlottesville. Her postgraduate training also includes a research fellowship at the Division of Experimental and Molecular Medicine, Scripps Clinic and Research Foundation, La Jolla, California; a medical oncology fellowship at the Division of Hematology/Oncology, University of California, San Diego Hospitals, and a research fellowship, Departments of Medicine and Biology, University of California, San Diego, School of Medicine, La Jolla.
Background - Randall K. Johnson, Ph.D.
Dr. Johnson, with over 30 years of experience in government and industry, has worked in all aspects of cancer drug discovery/development. This experience ranges from target validation, through screening technologies, basic research on mechanisms of drug action, assessment of efficacy in preclinical tumor models, to clinical development plans and regulatory strategies. He has put many drugs into clinical development and is credited with bringing topotecan to market.
After receiving a degree in Pharmacology, Dr. Johnson worked at the National Cancer Institute, at Arthur D Little, and for 20 years at GlaxoSmithKline / SmithKline Beecham Pharmaceuticals. He now consults for many pharmaceutical companies, both large and small, provides venture capital groups with assessment of investment opportunities and serves on the Scientific Advisory Boards of five other biotechnology companies.
About Array BioPharma:
Array BioPharma is creating the next generation of orally active drugs by integrating the latest advances in chemistry, biology and informatics. Our drug development pipeline is focused primarily in cancer and inflammatory disease and includes many promising small molecule drugs that regulate well- validated targets in therapeutically valuable disease pathways. Array also collaborates with leading pharmaceutical and biotechnology companies to invent and optimize drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com .
Forward-Looking Statement: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties, including those discussed in our annual report filed on Form 10-K for the fiscal year ended June 30, 2003, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to collaborate with and fund third parties on their drug discovery activities, the ability of our collaborators and of Array to meet drug discovery objectives tied to milestones and royalties, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, and our ability to attract and retain experienced scientists and management. We are providing this information as of February 19, 2004. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.
SOURCE Array BioPharma Inc.
Tricia Haugeto of Array BioPharma Inc., +1-303-386-1193, firstname.lastname@example.org /
/Web site: http://www.arraybiopharma.com / (ARRY)